tablets, Glaxo-Wellcome, for congestive heart failure, and control of ventricular rate in atrial fibrillation. On May 3, 1996, the committee will discuss product license application 95–1167, reteplase, Boehringer Mannheim, for management of acute myocardial infarction (AMI) in adults, lysis of thrombi obstructing coronary arteries, improvement of ventricular function following AMI, reduction of the incidence of congestive heart failure, and reduction of mortality associated with AMI.

FDA regrets that it was unable to publish this notice 15 days prior to the May 2, 1996, Cardiovascular and Renal Drugs Advisory Committee meeting. Because the agency feels that the issue needs to be brought to public discussion urgently, and qualified members of the Cardiovascular and Renal Drugs Advisory Committee were available at this time, the agency decided that it was in the public interest to hold this meeting even if there was not sufficient time for the customary 15-day public notice.

Arthritis Advisory Committee

Date, time, and place. May 7, 1996, 8 a.m., Holiday Inn—Gaithersburg, Whetstone and Walker Rooms, Two Montgomery Village Ave., Gaithersburg, MD.

Type of meeting and contact person. Open public hearing, 8 a.m. to 9 a.m., unless public participation does not last that long; open committee discussion, 9 a.m. to 5 p.m.; Kathleen R. Reedy, Center for Drug Evaluation and Research (HFD–21), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–443–5455, FAX 301–443–0699, or FDA Advisory Committee Information Hotline, 1–800–741–8138 (301–443–0572 in the Washington, DC area), Arthritis Advisory Committee, code 12532. Please call the hotline for information concerning any possible changes.

General function of committee. The committee reviews and evaluates data on the safety and effectiveness of marketed and investigational human drugs for use in arthritic conditions.

Agenda—Open public hearing. Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Those desiring to make formal presentations should notify the contact person before May 1, 1996, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time required to make their comments.

Open committee discussion. The committee will hear presentations and discuss data submitted regarding the safety and efficacy of NDA 20–395, Enable® (tenidap sodium), Pfizer, Inc., for use in the treatment of rheumatoid arthritis and osteoarthritis.

FDA regrets that it was unable to publish this notice 15 days prior to the May 7, 1996, Arthritis Advisory Committee meeting. Because the agency feels that the issue needs to be brought to public discussion urgently, and qualified members of the Arthritis Advisory Committee were available at this time, the agency decided that it was in the public interest to hold this meeting even if there was not sufficient time for the customary 15-day public notice.

FDA public advisory committee meetings may have as many as four separable portions: (1) An open public hearing, (2) an open committee discussion, (3) a closed presentation of data, and (4) a closed committee deliberation. Every advisory committee meeting shall have an open public hearing portion. Whether or not it also includes any of the other three portions will depend upon the specific meeting involved. There are no closed portions for the meetings announced in this notice. The dates and times reserved for the open portions of each committee meeting are listed above.

The open public hearing portion of each meeting shall be at least 1 hour long unless public participation does not last that long. It is emphasized, however, that the 1 hour time limit for an open public hearing represents a minimum rather than a maximum time for public participation, and an open public hearing may last for whatever longer period the committee chairperson determines will facilitate the committee's work.

Public hearings are subject to FDA's guideline (subpart C of 21 CFR part 10) concerning the policy and procedures for electronic media coverage of FDA's public administrative proceedings, including hearings before public advisory committees under 21 CFR part 14. Under 21 CFR 10.205, representatives of the electronic media may be permitted, subject to certain limitations, to videotape, film, or otherwise record FDA's public administrative proceedings, including presentations by participants.

Meetings of advisory committees shall be conducted, insofar as is practical, in accordance with the agenda published in this Federal Register notice. Changes in the agenda will be announced at the beginning of the open portion of a meeting.

Any interested person who wishes to be assured of the right to make an oral presentation at the open public hearing portion of a meeting shall inform the contact person listed above, either orally or in writing, prior to the meeting. Any person attending the hearing who does not in advance of the meeting request an opportunity to speak will be allowed to make an oral presentation at the hearing's conclusion, if time permits, at the chairperson's discretion.

The agenda, the questions to be addressed by the committee, and a current list of committee members will be available at the meeting location on the day of the meeting.

Transcripts of the open portion of the meeting may be requested in writing from the Freedom of Information Office (HFI–35), Food and Drug Administration, rm. 12A–16, 5600 Fishers Lane, Rockville, MD 20857, approximately 15 working days after the meeting, at a cost of 10 cents per page. The transcript may be viewed at the Dockets Management Branch (HFA–305), Food and Drug Administration, rm. 1–23, 12420 Parklawn Dr., Rockville, MD 20857, approximately 15 working days after the meeting, between the hours of 9 a.m. and 4 p.m., Monday through Friday. Summary minutes of the open portion of the meeting may be requested in writing from the Freedom of Information Office (address above) beginning approximately 90 days after the meeting.

This notice is issued under section 10(a)(1) and (2) of the Federal Advisory Committee Act (5 U.S.C. app. 2), and FDA's regulations (21 CFR part 14) on advisory committees.

Dated: April 18, 1996.

Michael A. Friedman,

Deputy Commissioner for Operations.

[FR Doc. 96–10047 Filed 4–23–96; 8:45 am]

BILLING CODE 4160–01–F

Health Resources and Services Administration

Agency Information Collection Activities: Submission for OMB Review; Comment Request

Periodically, the Health Resources and Services Administration (HRSA) publishes abstracts of information collection requests under review by the Office of Management and Budget, in compliance with the Paperwork Reduction Act of 1995 (44 U.S.C. Chapter 35). To request a copy of the clearance requests submitted to OMB for

review, call the HRSA Reports Clearance Office on (301)-443–1129.

The following request has been submitted to the Office of Management and Budget for review under the Paperwork Reduction Act of 1995:

Health Education Assistance Loan (HEAL) Program: Lender's Application for Insurance Claim on a HEAL Loan and Request for Collection Assistance Under the HEAL Program (currently approved under OMB Nos. 0915–0036 and 0915–0100)—Revision and Extension—This clearance request is for extension of approval of two forms that were previously approved by OMB under separate OMB numbers (shown above). HEAL lenders use the Lender's Application for Insurance Claim to request payment from the Federal Government for federally insured loans lost due to borrowers' death, disability, bankruptcy, or default. The Request for Collection Assistance form is used by HEAL lenders to request federal assistance with the collection of delinquent payments from HEAL borrowers. Minor changes were made to the Lender's Application for Insurance Claim, to reduce burden and improve the utility of the information. No substantive changes were made to the Request for Collection Assistance form. The estimates of burden for the two forms are as follows:

Type of form	No. of respondents	Responses per respondent	Burden per response	Total burden hours
Lender's Application for Insurance Claim (Form 510)	35	22.97	.50	402
Request for Collection Assistance (Form 513)	35	957.74	.17	5,598

Total burden is estimated to be 6,000 hours.

Written comments and recommendations concerning the proposed information collection should be sent within 30 days of this notice to: Virginia Huth, Human Resources and Housing Branch, Office of Management and Budget, New Executive Office Building, Room 10235, Washington, D.C. 20503.

Dated: April 18, 1996.

J. Henry Montes,

Associate Administrator for Policy Coordination.

[FR Doc. 96–10018 Filed 4–23–96; 8:45 am]

BILLING CODE 4160–15–P

National Institutes of Health

National Institute of Mental Health; Notice of Closed Meetings

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meetings of the National Institute of Mental Health Special Emphasis Panel:

Agenda/Purpose: To review and evaluate grant applications.

Committee Name: National Institute of Mental Health Special Emphasis Panel.

Date: April 23, 1996.

Time: 1 p.m.

Place: River Inn, 924 25th Street NW., Washington, DC 20037.

Contact Person: Phyllis L. Zusman, Parklawn Building, Room 9C–18, 5600 Fishers Lane, Rockville, MD 20857. Telephone: 301, 443–1340.

Committee Name: National Institute of Mental Health Special Emphasis Panel.

Date: April 23, 1996.

Time: 12 p.m.

Place: River Inn, 924 25th Street NW., Washington, DC 20037.

Contact Person: Phyllis L. Zusman, Parklawn Building, Room 9C–18, 5600 Fishers Lane, Rockville, MD 20857. Telephone: 301, 443–1340.

The meetings will be closed in accordance with the provisions set forth in secs. 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. Applications and/or proposals and the discussions could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the applications and/or proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

This notice is being published less than fifteen days prior to the meetings due to the urgent need to meet timing limitations imposed by the review and funding cycle.

(Catalog of Federal Domestic Assistance Program Numbers 93.242, 93.281, 93.282)

Dated: April 19, 1996.

Susan K. Feldman,

Committee Management Officer, NIH.

[FR Doc. 96–10182 Filed 4–20–96; 11:49 am]

BILLING CODE 4140–01–M

National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following National Institute of Allergy and Infectious Diseases Special Emphasis Panel (SEP) meeting:

Name of SEP: Master Agreement for HIV Preclinical Vaccine Development proposals, tasks G and I.

Date: April 25, 1996.

Time: 8:00 a.m.

Place: Washington National Airport Hilton Hotel, 2399 Jefferson Davis Highway, Arlington, VA 22202, (703) 418–6800.

Contact Person: Dr. Allen Stoolmiller, Scientific Review Adm., 6003 Executive Boulevard, Solar Bldg., Room 4C05, Bethesda, MD 20892–7610, (301) 496–7966.

Purpose/Agenda: To evaluate contract proposals.

The meeting will be closed in accordance with the provisions set forth in secs. 552(c)(4) and 552b(c)(6), Title 5, U.S.C. Applications and/or proposals and the discussions could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the applications and/or proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

This notice is being published less than 15 days prior to the meeting due to the urgent need to meet timing limitations imposed by the review and funding cycle.

(Catalog of Federal Domestic Assistance Programs Nos. 93.855, Immunology, Allergic and Immunologic Diseases Research; 93.856, Microbiology and Infectious Diseases Research, National Institutes of Health)

Dated: April 19, 1996.

Sustan K. Feldman,

Committee Management Officer, NIH.

[FR Doc. 96–10183 Filed 4–20–96; 11:49 am]

BILLING CODE 4140–01–M

National Institute of General Medical Sciences; Notice of Closed Meeting

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting:

Committee Name: National Institute of General Medical Sciences Special Emphasis Panel–MBRS.

Date: April 30.

Time: 8:00 a.m.–6 p.m.

Place: Gaithersburg Holiday Inn, Washington Conference Room, 2 Montgomery Village Avenue, Gaithersburg, Maryland 20879.

Contact Person: Dr. Richard Martinez, Scientific Review Administrator, NIGMS, 45 Center Drive, Room 1AS–19g, Bethesda, MD 20892–6200.

Purpose: To review grant applications.

The meeting will be closed in accordance with the provisions set forth in secs.